u/ferran_dahlberg

Push back: your plan is an employer plan, which changes both the appeal path and who the regulator is.

Agreed — protein and resistance training. Everything else in these threads is a rounding error on those two.

Which trial, and which arm?

Are we talking about receptor affinity or clinical potency?

step therapy is a documentation problem, not an argument

Cosigning on external review. It is a real mechanism, it is underused, and the deadlines are strict.

What does the discussion section say about the limitation you are glossing?

nothing on this board is a training or nutrition prescription

The fatigue turned out to be that I was eating about a third of what I thought I was. Tracked it for a week and the mystery evaporated.

This.

This is the concept everything else on this board is downstream of.

A symptom that begins the day after the shot and fades by day four tracks the exposure curve. One that appears at random in week 2 probably does not, and that is worth saying to a clinician rather than to us.

Cosigning that going too fast is the most repeated regret on the whole site.

Name removed.

ledger_mod is right that it was procedural. The procedure was not written down anywhere for you to follow.

What would have caught it earliest?

This is why the board exists. Nobody else publishes this part.

Agreed on the no-names rule. It protects the board and it protects people who turn out to be wrong.

The site had a decade of testimonials and a domain registered in March.

This is the check that catches most of it, and it takes under a minute.

the confidence interval is the finding, the point estimate is the headline

Small fix — that is fat-free mass, not muscle mass. The scan cannot separate them the way the post assumes.

if the price is impossible, the material is the thing being economised on

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

receptor distribution is why the side effects are where they are

if it is severe or persistent that is a clinician question, not a board question

Agreed. Slowing down at meals did more for my nausea than everything I bought to fix it, which was embarrassing to discover.

a mean is not a promise

This is the distinction that would end about half the arguments on this board.

Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.

somebody will read this at the point you were at, and it will help

Agreed — and being harder on yourself than you would be on somebody else posting the same thing is the pattern here.

Kept a one-line-a-day log for two months. The pattern was obvious on paper and invisible in my head.

The press release said that; the publication says something more hedged. Worth reading both.

Not convinced that was avoidable. Some of this is genuinely bad luck and treating everything as a lesson is its own trap.

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Resistance training, and at what frequency?

Constipation is mostly reduced intake plus reduced fluid, not a direct effect. That is why the boring fibre and water answer keeps working.

That was a hold rather than a loss, and it resolved. Updating rather than deleting.

Correcting myself: 2 weeks, not the figure I wrote. The story is the same and I had rounded it in my favour.

coming back to say you were wrong takes more than being right did

Fat-free mass index is a ratio of fat-free mass to height squared. It moves when either term does, which makes it awkward to interpret during active weight change.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Agreed — somebody is at exactly the point you were at, reading this, and it will land differently for them than any success story.

Right — mechanism gives you a direction.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.